Search results
Results from the WOW.Com Content Network
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States , South America , Asia , and Europe . BioMarin's core business and research is in enzyme replacement therapies (ERTs).
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
During his tenure at BioMarin, Kakkis guided the development and approval of two more treatments for rare disorders, MPS VI and PKU and has contributed to the initiation of seven other treatment programs for rare disorders, three of which are now in clinical development. Kakkis is board certified in both Pediatrics and Medical Genetics.
BioMarin taught big biotech companies a thing or two about making money this year. Here are three lessons large competitors likely learned watching BioMarin succeed in treating rare and ultra-rare ...
(Reuters) - BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the ...
For premium support please call: 800-290-4726 more ways to reach us
BioMarin stopped providing the drug for free at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered to keep doing so until ...
But to a lot of people the Sloan story is the first time they ever heard about Biomarin, and it pretty much all they know about the company. While the news coverage may have been biased and uniformed (I am not a supporter of Ms. Sloan), the fact that it was extensive makes it "notable" and thus suitable for inclusion in the article.